AIM AIM ImmunoTech Inc.
Price Chart
Executive Summary
AIM ImmunoTech announced ahead-of-schedule enrollment completion for its Phase 2 DURIPANC trial (Ampligen + Imfinzi in metastatic pancreatic cancer). Final subject enrollment closed before the original July 2026 target, with primary endpoint (Clinical Benefit Rate) evaluation planned for December 2026. This is a minor operational milestone for an early-stage, pre-revenue biotech with a $7M market cap and multiple prior neutral/bearish trading outcomes.
Actionable Insight
This is a minor operational update for a pre-revenue micro-cap. The enrollment completion is mildly positive but expected, and the stock has historically traded down on similar neutral/positive news. Key catalyst is the December 2026 CBR readout and the near-term interim report. Traders should not overweight this announcement given the company's cash constraints (likely need for financing before Phase 3) and the negative historical P&L on prior reports.
Key Facts
- Enrolled final subject in Phase 2 DURIPANC trial (Ampligen + Imfinzi for metastatic pancreatic cancer) ahead of the original July 2026 target.
- Final subject scheduled for treatment in mid-June 2026.
- Primary endpoint (Clinical Benefit Rate) evaluation planned for December 2026.
- Next interim report expected in 2–3 weeks.
- AIM has orphan drug designations in the US and Europe for Ampligen in pancreatic cancer.
- Company is a pre-revenue, early-stage biotech with a market cap of approximately $7M.
- Historical performance of prior reports on AIM shows negative average returns at T+5 and no settled T+20 data; the model has been over-scoring this ticker.
Financial Impact
No financial figures provided; pre-revenue company. Operational milestone only.
Risk Factors
- Pre-revenue company with ~$7M market cap — high cash-burn risk and likely need for dilutive financing before Phase 3 initiation.
- Pancreatic cancer trial is early stage (Phase 2, single-center, open-label); results may not replicate in larger, blinded Phase 3.
- Historical calibration shows past bullish/neutral reports on AIM have underperformed significantly at T+5.
- Final CBR readout not due until December 2026 — no near-term catalyst beyond interim report.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304404 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
8-K
| $0.4543 awaiting T+1 | awaiting T+1 | — | $0.4100 (+9.75%) |
|
Jun 10, 2026
2d ago
|
424B5
| $0.4477 awaiting T+1 | awaiting T+1 | — | $0.4100 (+8.42%) |
|
Jun 8, 2026
4d ago
|
Press Release
| $0.4589 awaiting T+1 | awaiting T+1 | — | $0.4100 (−10.66%) |
|
Jun 4, 2026
8d ago
|
8-K
| $0.5900 $0.5200 | ▼ −11.86% | ▼ −9.27% | $0.4100 (−30.51%) |
|
Jun 1, 2026
11d ago
|
Press Release
| $0.9000 $0.8300 | ▼ −7.78% | ▼ −7.92% | $0.4100 (−54.44%) |
|
May 21, 2026
22d ago
|
8-K
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.4100 (−70.83%) |
|
May 21, 2026
22d ago
|
424B5
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.4100 (−70.83%) |
|
May 20, 2026
23d ago
|
Press Release
| $0.2500 $0.2400 | ▲ +4.00% | ▲ +4.19% | $0.4100 (−64.00%) |
|
May 19, 2026
24d ago
|
424B5
| $0.2500 $0.2400 | ▼ −4.00% | ▼ −4.19% | $0.4100 (+64.00%) |
|
May 19, 2026
24d ago
|
8-K
| $0.4100 $0.2500 | ▼ −39.02% | ▼ −40.06% | $0.4100 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access